Zhigang Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhigang Yuan has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Iman Imanirad
Department of Gastrointestinal Oncology,H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL33612, USA
2 shared publications- Jessica M. Frakes
Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
2 shared publications Julian Sanchez
Department of Gastrointestinal Oncology,H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL33612, USA
2 shared publicationsMarissa Frazer
Department of Radiation Oncology,H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL33612, USA
2 shared publicationsRichard D Kim
Department of Gastrointestinal Oncology,H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL33612, USA
2 shared publicationsSarah E Hoffe
Department of Radiation Oncology,H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL33612, USA
2 shared publications
Latest Publications
- Open Access
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 6 (6) , 1510-1518
Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment
Cervical cancer remains a major health challenge in low- to middle-income countries. We present the experiences of two centers practicing in variable resource environments to determine predictors of improved radiochemotherapy treatment. This comparative review describes cervical cancer presentation and treatment with concurrent chemoradiotherapy with high-dose-rate brachytherapy between 2014 and 2017 at the National Radiotherapy Oncology and Nuclear Medicine Center (NRONMC) in Korle-Bu Teaching Hospital, Accra, Ghana, and Moffitt Cancer Center (MCC), Tampa, FL. Median follow-up for this study was 16.9 months. NRONMC patients presented with predominantly stage III disease (42% v 16%; P = .002). MCC patients received para-aortic node irradiation (16%) and interstitial brachytherapy implants (19%). Median treatment duration was longer for NRONMC patients compared with MCC patients (59 v 52 days; P < .0001), and treatment duration ≥ 55 days predicted worse survival on multivariable analysis (MVA; P = .02). Stage ≥ III disease predicted poorer local control on MVA. There was a difference in local control among patients with stage III disease (58% v 91%; P = .03) but not in survival between MCC and NRONMC. No significant difference in local control was observed for stage IB, IIA, and IIB disease. Although there were significant differences in disease presentation between the two centers, treatment outcomes were similar for patients with early-stage disease. Longer treatment duration and stage ≥ III disease predicted poor outcomes.
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 6 (6) , 1510-1518
Open AccessComparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment
Cervical cancer remains a major health challenge in low- to middle-income countries. We present the experiences of two centers practicing in variable resource environments to determine predictors of improved radiochemotherapy treatment. This comparative review describes cervical cancer presentation and treatment with concurrent chemoradiotherapy with high-dose-rate brachytherapy between 2014 and 2017 at the National Radiotherapy Oncology and Nuclear Medicine Center (NRONMC) in Korle-Bu Teaching Hospital, Accra, Ghana, and Moffitt Cancer Center (MCC), Tampa, FL. Median follow-up for this study was 16.9 months. NRONMC patients presented with predominantly stage III disease (42% v 16%; P = .002). MCC patients received para-aortic node irradiation (16%) and interstitial brachytherapy implants (19%). Median treatment duration was longer for NRONMC patients compared with MCC patients (59 v 52 days; P < .0001), and treatment duration ≥ 55 days predicted worse survival on multivariable analysis (MVA; P = .02). Stage ≥ III disease predicted poorer local control on MVA. There was a difference in local control among patients with stage III disease (58% v 91%; P = .03) but not in survival between MCC and NRONMC. No significant difference in local control was observed for stage IB, IIA, and IIB disease. Although there were significant differences in disease presentation between the two centers, treatment outcomes were similar for patients with early-stage disease. Longer treatment duration and stage ≥ III disease predicted poor outcomes.
- 20 July 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (30) , 2411-2420
Modeling precision genomic-based radiation dose response in rectal cancer
Aim: Genomic-based risk stratification to personalize radiation dose in rectal cancer. Patients & methods: We modeled genomic-based radiation dose response using the previously validated radiosensi...
- 20 July 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (30) , 2411-2420
Modeling precision genomic-based radiation dose response in rectal cancer
Aim: Genomic-based risk stratification to personalize radiation dose in rectal cancer. Patients & methods: We modeled genomic-based radiation dose response using the previously validated radiosensi...
- 9 May 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (3) , 444-449
CT‐based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study
Introduction: Innovative biomarkers to predict treatment response in rectal cancer would be helpful in optimizing personalized treatment approaches. In this study, we aimed to develop and validate a CT‐based radiomic imaging biomarker to predict pathological response.Methods: We used two independent cohorts of rectal cancer patients to develop and validate a CT‐based radiomic imaging biomarker predictive of treatment response. A total of 91 rectal cancer cases treated from 2009 to 2018 were assessed for the tumour regression grade (TRG) (0 = pathological complete response, pCR; 1 = moderate response; 2 = partial response; 3 = poor response). Exploratory analysis was performed by combining pre‐treatment non‐contrast CT images and patterns of TRG. The models built from the training cohort were further assessed using the independent validation cohort.Results: The patterns of pathological response in training and validation groups were TRG 0 (n = 14, 23.3%; n = 6, 19.4%), 1 (n = 31, 51.7%; n = 15, 48.4%), 2 (n = 12, 20.0%; n = 7, 22.6%) and 3 (n = 3, 5.0%; n = 3, 9.7%), respectively. Separate predictive models were built and analysed from CT features for pathological response. For pathological response prediction, the model including 8 radiomic features by random forest method resulted in 83.9% accuracy in predicting TRG 0 vs TRG 1–3 in validation.Conclusion: The pre‐treatment CT‐based radiomic signatures were developed and validated in two independent cohorts. This imaging biomarker provided a promising way to predict pCR and select patients for non‐operative management.
- 9 May 2020
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 64 (3) , 444-449
CT‐based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study
Introduction: Innovative biomarkers to predict treatment response in rectal cancer would be helpful in optimizing personalized treatment approaches. In this study, we aimed to develop and validate a CT‐based radiomic imaging biomarker to predict pathological response.Methods: We used two independent cohorts of rectal cancer patients to develop and validate a CT‐based radiomic imaging biomarker predictive of treatment response. A total of 91 rectal cancer cases treated from 2009 to 2018 were assessed for the tumour regression grade (TRG) (0 = pathological complete response, pCR; 1 = moderate response; 2 = partial response; 3 = poor response). Exploratory analysis was performed by combining pre‐treatment non‐contrast CT images and patterns of TRG. The models built from the training cohort were further assessed using the independent validation cohort.Results: The patterns of pathological response in training and validation groups were TRG 0 (n = 14, 23.3%; n = 6, 19.4%), 1 (n = 31, 51.7%; n = 15, 48.4%), 2 (n = 12, 20.0%; n = 7, 22.6%) and 3 (n = 3, 5.0%; n = 3, 9.7%), respectively. Separate predictive models were built and analysed from CT features for pathological response. For pathological response prediction, the model including 8 radiomic features by random forest method resulted in 83.9% accuracy in predicting TRG 0 vs TRG 1–3 in validation.Conclusion: The pre‐treatment CT‐based radiomic signatures were developed and validated in two independent cohorts. This imaging biomarker provided a promising way to predict pCR and select patients for non‐operative management.
- Open Access
- 16 September 2013
- Published by China Science Publishing & Media Ltd. in HEREDITAS
- Vol. 35 (11) , 1300-1306
Analysis of SCA3/MJD3 gene mutation and genetic polymorphism in a Guangxi family with spinocerebellar ataxia 3
Autosomal dominant cerebellar ataxias (ADCAs) comprise a group of genetically heterogeneous neurodegenerative disorders among which spinocerebellar ataxia type 3 (SCA3) represents the most common form of SCAs worldwide. The fragments of SCA3/MJD gene,which is the member of family GXPL1,were amplified by polymerase chain reaction (PCR). The PCR products of SCA3/MJD gene were detected with capillary electrophoresis (CE) and sequencing to evaluate the size of CAG repeats, feature in the transmission and the mutation in the family with SCA3 in Guangxi province. The results showed that the exon 10 of the SCA3/MJD gene contains 64-71 CAG repeats in all of the affected individuals and three asymptomatic carriers of the family. The number of the CAG repeats during transmission in the normal individuals carrying CGG allele remains consistent, suggesting that CGG allele could have no effect on intergenerational stability of CAG repeats in normal individuals. In addition, two novel point mutations were identified: IVS9-113 T > C in the intronic region and a missense mutation 220 G > A (Glu > Gly) in the encoding region. These two novel point mutations have not been reported and the effect of the mutations on the phenotype of SCA3 is not clear.
- 16 September 2013
- Published by China Science Publishing & Media Ltd. in HEREDITAS
- Vol. 35 (11) , 1300-1306
Open AccessAnalysis of SCA3/MJD3 gene mutation and genetic polymorphism in a Guangxi family with spinocerebellar ataxia 3
Autosomal dominant cerebellar ataxias (ADCAs) comprise a group of genetically heterogeneous neurodegenerative disorders among which spinocerebellar ataxia type 3 (SCA3) represents the most common form of SCAs worldwide. The fragments of SCA3/MJD gene,which is the member of family GXPL1,were amplified by polymerase chain reaction (PCR). The PCR products of SCA3/MJD gene were detected with capillary electrophoresis (CE) and sequencing to evaluate the size of CAG repeats, feature in the transmission and the mutation in the family with SCA3 in Guangxi province. The results showed that the exon 10 of the SCA3/MJD gene contains 64-71 CAG repeats in all of the affected individuals and three asymptomatic carriers of the family. The number of the CAG repeats during transmission in the normal individuals carrying CGG allele remains consistent, suggesting that CGG allele could have no effect on intergenerational stability of CAG repeats in normal individuals. In addition, two novel point mutations were identified: IVS9-113 T > C in the intronic region and a missense mutation 220 G > A (Glu > Gly) in the encoding region. These two novel point mutations have not been reported and the effect of the mutations on the phenotype of SCA3 is not clear.
- Open Access
- 1 December 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (23) , 2869-2871
A Functional Link Between SIRT1 Deacetylase and NBS1 in DNA Damage Response
In mammalian cells, DNA is often subjected to stresses such as ionizing radiation (IR) and ultraviolet light that can induce DNA double strand breaks (DSBs). In response to DNA DSBs, mammalian cell...
- 1 December 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (23) , 2869-2871
Open AccessA Functional Link Between SIRT1 Deacetylase and NBS1 in DNA Damage Response
In mammalian cells, DNA is often subjected to stresses such as ionizing radiation (IR) and ultraviolet light that can induce DNA double strand breaks (DSBs). In response to DNA DSBs, mammalian cell...